David K. Lau

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Cost-consequence analysis of models of general medicine perioperative care in Victorian hospitals.

Cost-consequence analysis of models of general medicine perioperative care in Victorian hospitals.

Journal: Internal medicine journal

Published: May 10, 2026

What do general medicine perioperative services do? A Victorian multicentre cross-sectional study.

What do general medicine perioperative services do? A Victorian multicentre cross-sectional study.

Journal: Internal medicine journal

Published: July 03, 2025

Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer.

Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer.

Journal: Biomedicines

Published: March 21, 2024

Outcomes of de-prescribing proton pump inhibitors during acute admissions in a general medical unit: a pilot study.

Outcomes of de-prescribing proton pump inhibitors during acute admissions in a general medical unit: a pilot study.

Journal: Internal medicine journal

Published: November 08, 2022

Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials.

Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials.

Journal: Frontiers in oncology

Published: June 07, 2022

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.

Journal: BMC cancer

Published: October 28, 2021

Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK.

Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK.

Journal: Molecular cancer therapeutics

Published: September 29, 2020

Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets.

Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets.

Journal: iScience

Published: July 05, 2019

Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy.

Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: May 17, 2019

The demise of Angkor: Systemic vulnerability of urban infrastructure to climatic variations.

The demise of Angkor: Systemic vulnerability of urban infrastructure to climatic variations.

Journal: Science advances

Published: June 06, 2018

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.

Journal: British journal of cancer

Published: December 01, 2017

Oral versus intravenous fluoropyrimidines for colorectal cancer.

Oral versus intravenous fluoropyrimidines for colorectal cancer.

Journal: The Cochrane database of systematic reviews

Published: July 29, 2017

Showing 1-12 of 15

Last Updated: 09/26/2026